Proteolysis during Tumor Cell Extravasation In Vitro: Metalloproteinase Involvement across Tumor Cell Types

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Voura, Evelyn B ^a,b   English, Jane L ^a   Yu, Hoi Ying E ^a   Ho, Andrew T ^a   Subarsky, Patrick ^a   Hill, Richard P ^a   Hojilla, Carlo V ^a   Khokha, Rama ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Dominican College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA V BETA 3; FURIN; GELATINASE A; GELATINASE B; HERMES ANTIGEN; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; PROTEINASE; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE;

ARTICLE; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PROTEIN DEGRADATION; REGULATORY MECHANISM; TUMOR CELL; TUMOR CELL EXTRAVASATION; ANTAGONISTS AND INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHYSIOLOGY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL ADHESION MOLECULES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN VITRO TECHNIQUES; METALLOPROTEASES; MICROSCOPY, CONFOCAL; PROTEOLYSIS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84885970985     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078413     Document Type: Article

References (68)

1. Dufour A, Overall CM, (2013) Missing the target: matrix metalloproteinase antitargets in inflammation and cancer CM. Trends Pharmacol Sci 34: 233-242. doi:10.1016/j.tips.2013.02.004. PubMed: 23541335.
2. Butler GS, Overall CM, (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov 8: 935-948. doi:10.1038/nrd2945. PubMed: 19949400.
3. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174. doi:10.1038/nrc745. PubMed: 11990853.
4. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, et al. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331-5338. doi:10.1074/jbc.270.10.5331. PubMed: 7890645.
5. Hernandez-Barrantes S, Toth M, Bernardo MM, Yurkova M, Gervasi DC, et al. (2000) Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 275: 12080-12089. doi:10.1074/jbc.275.16.12080. PubMed: 10766841.
6. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ, (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344. doi:10.1046/j.1523-1747.2000.00068.x. PubMed: 10951266.
7. Overall CM, Tam E, McQuibban GA, Morrison C, Wallon UM, et al. (2000) Domain interactions in the gelatinase A-TIMP-2-MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem 275: 39497-39506. doi:10.1074/jbc.M005932200. PubMed: 10991943.
8. Basbaum CB, Werb Z, (1996) Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 8: 731-738. doi:10.1016/S0955-0674(96)80116-5. PubMed: 8939664.
9. Yana I, Weiss SJ, (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Cell Biol 11: 2387-2401. doi:10.1091/mbc.11.7.2387. PubMed: 10888676.
10. Remacle AG, Rozanov DV, Fugere M, Day R, Strongin AY, (2006) Furin Regulates the intracellular activation and the uptake rate of cell surface- associated MT1-MMP. Oncogene 25: 5648-5655. doi:10.1038/sj.onc.1209572. PubMed: 16636666.
11. Golubkov VS, Chernov AV, Strongin AY, (2011) Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo. J Biol Chem 286: 34215-34223. doi:10.1074/jbc.M111.264036. PubMed: 21832072.
12. Coppola JM, Bhojani MS, Ross RD, Rehemtulla A, (2008) A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10: 363-370. PubMed: 18392131.
13. Sato T, Kondo T, Fujisawa T, Seiki M, Ito A, (1999) Furin-independent pathway of membrane type 1-matrix metalloproteinase activation in rabbit dermal fibroblasts. J Biol Chem 274: 37280-37284. doi:10.1074/jbc.274.52.37280. PubMed: 10601293.
14. Rozanov DV, Deryugina EI, Ratnikov BI, Monosov EZ, Marchenko GN, et al. (2001) Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys-574, the active site Glu-240 and furin cleavage motifs in oligomerization, procession and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. J Biol Chem 276: 25705-25714. doi:10.1074/jbc.M007921200. PubMed: 11335709.
15. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, et al. (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16: 2319-2332. doi:10.1093/emboj/16.9.2319. PubMed: 9171346.
16. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, et al. (1996) Localization of Matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85: 638-693.
17. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA, (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391-400. doi:10.1016/S0092-8674(00)80931-9. PubMed: 9476898.
18. Ivaska J, Heino J, (2000) Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci 57: 16-24. doi:10.1007/s000180050496. PubMed: 10949578.
19. Rupp RA, Visconti RP, Czirok A, Cheresh DA, Little CD, (2008) Matrix metalloproteinase 2-integrin αvβ3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Cell Biol 19: 5529-5540. doi:10.1091/mbc.E07-05-0480.
20. Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, et al. (2005) Transmigration of human ovarian adenocarcinooma cells through endothelial extracellular matrix involves αv integrins and the participation of MMP2. Int J Cancer 114: 531-543. doi:10.1002/ijc.20778. PubMed: 15609323.
21. Kargozaran H, Yuan SY, Breslin JW, Watson KD, Gaudreault N, et al. (2007) A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis 24: 495-502. doi:10.1007/s10585-007-9086-6. PubMed: 17653824.
22. Jiao Y, Feng X, Zhan Y, Wang R, Zheng S, et al. (2012) Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLOS ONE 7: e41591. doi:10.1371/journal.pone.0041591. PubMed: 22848537.
23. Steffensen B, Bigg HF, Overall CM, (1998) The involvement of the fibronectin type II-like of human gelatinase A in cell surface localization and activation. J Biol Chem 273: 20622-20628. doi:10.1074/jbc.273.32.20622. PubMed: 9685420.
24. Ellerbroek SM, Stack MS, (1999) Membrane associated matrix metalloproteinases in metastasis. BioEssays 21: 940-949. doi:10.1002/(SICI)1521-1878(199911)21:11. PubMed: 10517867.
25. Albelda SM, Mette SA, Elder DE, (1990) Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 50: 6757-6764. PubMed: 2208139.
26. Thomas L, Byers HR, Vink J, Stamenkovic I, (1992) CD44H regulates tumor cell migration of hyaluronate-coated substrate. J Cell Biol 118: 971-977. doi:10.1083/jcb.118.4.971. PubMed: 1380003.
27. Bourguignon LY, Gunja-Smith Z, Iida N, Young LJ, Muller WJ, et al. (1998) CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 176: 206-215. doi:10.1002/(SICI)1097-4652(199807)176:1. PubMed: 9618160.
28. Yu Q, Stamenkovic I, (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13: 35-48. doi:10.1101/gad.13.1.35. PubMed: 9887098.
29. Yu Q, Stamenkovic I, (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176. PubMed: 10652271.
30. Kajita M, Itoh Y, Chiba T, (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153: 893-904. doi:10.1083/jcb.153.5.893. PubMed: 11381077.
31. Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, et al. (2002) CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 21: 3949-3959. doi:10.1093/emboj/cdf411. PubMed: 12145196.
32. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, Hernandez del Cerro M, Van den Steen PE, et al. (2008) α4β1 and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169-178. doi:10.1182/blood-2007-08-109249. PubMed: 18326820.
33. Desai B, Ma T, Zhu J, Chellaiah MA, (2009) Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 108: 272-284. doi:10.1002/jcb.22248. PubMed: 19582779.
34. Fang XJ, Jiang H, Zhao XP, Jiang WM, (2011) The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7. BMC Cancer 11: 290-300. doi:10.1186/1471-2407-11-290. PubMed: 21749678.
35. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, et al. (2003) Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160: 267-277. doi:10.1083/jcb.200209006. PubMed: 12527751.
36. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, et al. (1994) Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54: 4791-4797. PubMed: 8062280.
37. Deryugina EI, Quigley JP, (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34. doi:10.1007/s10555-006-7886-9. PubMed: 16680569.
38. Voura EB, Sandig M, Kalnins VI, Siu CH, (1998) Cell shape changes and cytoskeleton reorganization during transendothelial migration of human melanoma cells. Cell Tissue Res 293: 375-387. doi:10.1007/s004410051129. PubMed: 9716727.
39. Voura EB, Sandig M, Siu CH, (1998) Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech 43: 265-275. doi:10.1002/(SICI)1097-0029(19981101)43:3. PubMed: 9840805.
40. Voura EB, Chen N, Kalnins VI, Siu CH, (2000) Platelet-endothelial cell adhesion molecule-1 (CD31) redistributes from the endothelial junction and is not required for the transendothelial migration of melanoma cells. Clin Exp Metastasis 18: 527-532. doi:10.1023/A:1011884807746. PubMed: 11592310.
41. Sandig M, Voura EB, Kalnins VI, Siu CH, (1997) Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell Motil Cytoskel 38: 351-364. doi:10.1002/(SICI)1097-0169(1997)38:4. PubMed: 9415377.
42. Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH, (2001) Involvement of the integrin αvβ3 and the cell adhesion molecule L1 in the transendothelial migration of melanoma cells. Mol Cell Biol 12: 2699-2710. doi:10.1091/mbc.12.9.2699.
43. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, et al. (1999) Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274: 21056-21062. doi:10.1074/jbc.274.30.21056. PubMed: 10409657.
44. Hotary K, Allen E, Punturieri A, Yana I, Weiss WJ, (2000) Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 149: 1309-1323.
45. Overall CM, King AE, Sam DK, Ong AD, Lau TT, et al. (1999) Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. J Biol Chem 274: 4421-4429. doi:10.1074/jbc.274.7.4421. PubMed: 9933646.
46. Angliker H, Wikstrom P, Shaw E, Brenner C, Fuller RS, (1993) The synthesis of inhibitors for processing proteases and their action on the Kex2 protease of yeast. Biochem J 293: 75-81. PubMed: 8328974.
47. Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G, et al. (1998) Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 424: 262-266. doi:10.1016/S0014-5793(98)00187-2. PubMed: 9539163.
48. Ramos-DeSimone N, Moll UM, Quigley JP, French DL, (1993) Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma 12: 349-363. doi:10.1089/hyb.1993.12.349. PubMed: 8244415.
49. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, et al. (1994) Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha v beta 3, and alpha 5 beta 1 integrins. J Biol Chem 269: 20233-20238.
50. Krüger A, Fata JE, Khokha R, (1997) Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood 90: 1993-2000. PubMed: 9292534.
51. Krüger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, et al. (1998) Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16: 2419-2423. doi:10.1038/sj.onc.1201774. PubMed: 9620561.
52. Bauvois B, (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36. PubMed: 22020293.
53. Kasaoka T, Nishiyama H, Okada M, Nakajima M, (2008) Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin Exp Metastasis 25: 827-834. doi:10.1007/s10585-008-9198-7. PubMed: 18668328.
54. Rozanov DV, Strongin AY, (2003) Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem 278: 8257-8260. doi:10.1074/jbc.M213246200. PubMed: 12514192.
55. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, et al. (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 167: 769-781. doi:10.1083/jcb.200408028. PubMed: 15557125.
56. Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, et al. (1999) Airway epithelial cell migration dynamics: MMP-9 role in cell extracellular matrix remodeling. J Cell Biol 146: 517-529. doi:10.1083/jcb.146.2.517. PubMed: 10427102.
57. Dolo V, Adobati E, Canevari S, Picone AM, Vittorelli ML, (1995) Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 4: 277-286. PubMed: 7606890.
58. Poste G, Nicolson GL, (1980) Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci U_S_A 77: 399-403. doi:10.1073/pnas.77.1.399. PubMed: 6928631.
59. Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli ML, (1994) Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 26: 173-180. PubMed: 8019942.
60. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, et al. (1997) Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272: 17216-17222. doi:10.1074/jbc.272.27.17216. PubMed: 9202045.
61. Dolo V, Ginestra A, Cassarà D, Violini S, Lucania G, et al. (1998) Selective localization of matrix metalloproteinase 9, beta 1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 58: 4468-4474. PubMed: 9766680.
62. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, et al. (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17: 131-140. doi:10.1023/A:1006500406240. PubMed: 10411105.
63. Gioia M, Monaco S, Van Den Steen PE, Sbardella D, Grasso G, et al. (2009) The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J Mol Biol 386: 419-434. doi:10.1016/j.jmb.2008.12.021. PubMed: 19109975.
64. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J, (2010) Role of matrix metalloproteinase-9 dimers in cell migation design of inhibitory peptides. J Biol Chem 285: 35944-35956. doi:10.1074/jbc.M109.091769. PubMed: 20837483.
65. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, et al. (2013) RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLOS ONE 8: e63153. doi:10.1371/journal.pone.0063153. PubMed: 23696795.
66. Desch A, Strozyk EA, Bauer AT, Huck V, Niemeyer V, et al. (2012) Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A. Am J Pathol 181: 693-705. doi:10.1016/j.ajpath.2012.04.012. PubMed: 22659470.
67. Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, et al. (2012) Angiotensin II facilitates breast cancer cell migration and metastasis. PLOS ONE 7: e35667. doi:10.1371/journal.pone.0035667. PubMed: 22536420.
68. Stellas D, Haidieh AE, Patsavoudi E, (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disruption their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11: 51. doi:10.1186/1471-2121-11-51. PubMed: 20602761.